What if you'd held SUPN?
A $1,000 investment in Supernus Pharmaceuticals, Inc. (SUPN) at the month-end close of 2012-05 would be worth $8,842 at the close of 2026-08 — +784.2% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $5,882.
Your scenario
Result
If you'd bought $1,000 at the start of each year
Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.
Every year, $1,000 from 2012
| Year | Value of $1,000 | Year return |
|---|---|---|
| 2012 | $1,000 | — |
| 2013 | $1,052 | +5.2% |
| 2014 | $1,158 | +10.1% |
| 2015 | $1,874 | +61.9% |
| 2016 | $3,522 | +87.9% |
| 2017 | $5,558 | +57.8% |
| 2018 | $4,633 | -16.6% |
| 2019 | $3,308 | -28.6% |
| 2020 | $3,509 | +6.1% |
| 2021 | $4,067 | +15.9% |
| 2022 | $4,975 | +22.3% |
| 2023 | $4,036 | -18.9% |
| 2024 | $5,043 | +24.9% |
| 2025 | $6,932 | +37.4% |
| 2026 | $6,770 | -2.3% |
Best and worst month-end to buy
The best single month-end close to have bought SUPN was 2013-04 ($5.14): $1,000 then is $9,444 today. The worst was 2018-06 ($59.85): $1,000 then is $811.
FAQ
What would $1,000 in SUPN be worth today?
A $1,000 investment in Supernus Pharmaceuticals, Inc. (SUPN) at the start of 2012 would be worth about $8,842 today, a total return of +784.2%. Dividends are reinvested in these figures.
What were the best and worst years for SUPN?
Supernus Pharmaceuticals, Inc. (SUPN)'s strongest calendar year since 2012 was 2016, a +87.9% return — $1,000 held through that year became about $1,879 by year-end. Its weakest year was 2019, at -28.6%.
Does the calculator include dividends and splits?
Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.
How much would $100 per month in SUPN have grown?
Investing $100 at the end of every month since 2012-05 would have grown to about $44,437 on $17,200 invested.
Did SUPN beat the S&P 500?
Over the same period, $1,000 in the S&P 500 index would be worth $5,882. SUPN beat the S&P 500 by +50.3% in total return.
Is this investment advice?
No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.
Methodology
Supernus Pharmaceuticals, Inc. (SUPN) historical total-return data from 2012-05 to 2026-08, reduced to month-end closes for the tables above.
Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.
Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.
What if you'd held…
Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.